Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-cash Items (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Non-cash Items for 7 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items rose 1574.7% to $5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Dec 2025, up 1574.7% year-over-year, with the annual reading at $5.7 million for FY2025, 26.16% up from the prior year.
  • Non-cash Items for Q4 2025 was $5.7 million at 4D Molecular Therapeutics, down from $6.0 million in the prior quarter.
  • The five-year high for Non-cash Items was $48.0 million in Q4 2022, with the low at $342000.0 in Q4 2024.
  • Average Non-cash Items over 5 years is $8.6 million, with a median of $3.2 million recorded in 2023.
  • The sharpest move saw Non-cash Items plummeted 99.27% in 2024, then surged 1574.7% in 2025.
  • Over 5 years, Non-cash Items stood at $24.7 million in 2021, then surged by 94.8% to $48.0 million in 2022, then dropped by 2.47% to $46.9 million in 2023, then tumbled by 99.27% to $342000.0 in 2024, then surged by 1574.7% to $5.7 million in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $5.7 million, $6.0 million, and $5.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.